This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Independent Clinical Research Confirms Clinical Efficacy And Cost-Effectiveness Of The SurgiCount Safety-Sponge® System

IRVINE, Calif. and DUBLIN, Ohio, Jan. 18, 2011 /PRNewswire/ -- Results of a multi-year, independent clinical research study on retained surgical sponges published in the February edition of The Joint Commission Journal on Quality and Patient Safety show that the institution implementing the SurgiCount Safety-Sponge® System eliminated the occurrence of retained surgical sponges and the costs associated with these preventable surgical errors.  

The peer-reviewed publication details two, randomized, controlled trials conducted at a high-volume surgical practice, the subsequent implementation of the Safety-Sponge® System across all of the 128 operating rooms at the affiliated institution and a comprehensive evaluation of the solution after 18 months of use. The evaluation considered variables including system effectiveness on reducing retained surgical sponges, efficiency, impact on operative time, ergonomics and staff satisfaction.      

Key results and conclusions of the study include:

  • Prior to implementation, a retained surgical sponge occurred at the institution on average every 64 days. During the study, 87,404 procedures were performed over 18 months using 1,862,373 Safety-Sponges®, and none were retained.  
  • Use of the Safety-Sponge® System caused no workflow disruption or increase in case duration.
  • Staff satisfaction with the Safety-Sponge® System was acceptable with a high degree of trust in the system.
  • The Safety-Sponge® System was found to be highly reliable and cost-effective.

"To my knowledge this is by far the most extensive study ever performed on this important patient safety issue, and we are proud to have this comprehensive, independent research validate the SurgiCount Safety-Sponge® System," said Brian E. Stewart, president and chief executive officer of Patient Safety Technologies, the parent company of SurgiCount Medical, and co-inventor of the Safety-Sponge® System.

The SurgiCount Safety-Sponge® System is a complete sponge counting and documentation system shown to help prevent the occurrence of retained sponges by assuring a more accurate accounting of those items before and after surgery. By labeling each sponge with a unique identifier, the system helps to prevent users from incorrectly counting the individual sponges and unintentionally leaving one inside the patient. The system is currently used in more than 65 government, teaching and community hospitals across the U.S., including five of the 14 "Honor Roll Hospitals" for 2010-2011, as cited by U.S. News and World Report.

"Avoidable medical errors cost the U.S. health care industry an estimated $20 billion every year and put patient lives in jeopardy(1)," said Lisa Ashby, president, Category Management for the Medical Segment of Cardinal Health. "We work continuously with partners like SurgiCount to connect our customers to innovative, cost-effective solutions that help reduce errors and increase the quality of care, and these results confirm that we're making a positive impact on the future of health care."

The Safety-Sponge® System is a proprietary product provided by SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies (OTC Bulletin Board: PSTX), and distributed by Cardinal Health (NYSE: CAH).

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs